Biometrix Ltd

Biometrix Ltd specializes in advanced medical technologies that enhance diagnostics and therapeutic interventions within the healthcare sector, focusing on innovative solutions for cardiology and neurology. Biometrix Ltd, founded in 1985 in Jerusalem, Israel, delivers advanced medical diagnostic and therapeutic technologies. The company was acquired by Degania Silicone, a portfolio company of Viola Group, in May 2012, with financial terms undisclosed. The founder, Muhammad Bin Ajmal, has not been noted for founding other companies prior to Biometrix.

Biometrix Medical specializes in advanced medical technologies that enhance diagnostics and therapeutic interventions in the healthcare sector. The company’s core offerings include innovative diagnostic tools and devices designed for a range of medical applications, particularly in the fields of cardiology and neurology. These products are engineered to improve patient outcomes through accurate data collection and analysis, thereby assisting healthcare professionals in making informed decisions. Biometrix Medical primarily serves hospitals, clinics, and specialized healthcare facilities across North America and Europe, leveraging partnerships with healthcare providers to ensure their technologies meet the specific needs of end-users.

The products are developed with an emphasis on usability and integration into existing healthcare systems, thereby streamlining workflows for medical professionals. Biometrix Medical generates revenue through direct sales of its proprietary medical devices and diagnostic tools to healthcare institutions. The transaction structure primarily consists of B2B sales, where hospitals and clinics procure these devices through one-time purchases or multi-year contracts. Revenue streams may also include service agreements for maintenance and support, providing ongoing assistance to clients to ensure optimal performance of the devices.

Flagship products command premium pricing, reflecting their advanced technological features and the value they offer in clinical settings. This structured approach to revenue generation allows Biometrix Medical to build long-term relationships with clients while addressing their evolving healthcare needs. Biometrix Ltd is focused on expanding its product line with new diagnostic devices designed for cardiology and neurology, aiming for a rollout over the next two years. The company plans to enter new markets in Asia and South America by the end of 2024, leveraging its existing partnerships to facilitate this growth.

The acquisition by Degania Silicone in May 2012 will support these initiatives by providing additional resources for product development and market expansion.